A CLINICAL STUDY TO EVALUATE THE EFFICACY OF ASHTANGA GHRITA IN THE MANAGEMENT OF CHITTODVEGA WITH SPECIAL REFERENCE TO GENERALIZED ANXIETY DISORDER.

Completed

Brief Summary: THIS STUDY IS PUT FORWARD TO EVALUATE THE EFFICACY OF ASHTANGA GHR

Recruitment & Eligibility

Inclusion Criteria

1.SUBJECTS SUFFERING FROM GENERALIZED ANXIETY DISORDER BETWEEN AGE GROUP OF 20 TO 60 YEARS IRRESPECTIVE OF GENDER SOCIO ECONOMIC STATUS AND RELIGION.
2.SUBJECTS PRESENTING WITH PROMINENT TENSION WORRY AND FEELINGS OF APPREHENSION ABOUT EVERY-DAY EVENTS AND PROBLEMS FOR A MINIMUM PERIOD OF AT LEAST SIX MONTHS.
3.SUBJECTS FULFILLING CRITERIA BASED ON ICD 10 F41 1 CLASSIFICATION OF MENTAL AND BEHAVIOURAL DISORDERS CODE F41 1 AND THOSE GET SCORE BETWEEN 14-24 IN HAMILTON ANXIETY RATING SCALE MILD 14-17 AND MODERATE 18-24 WILL BE INCLUDED IN THE STUDY.

Exclusion Criteria

SUBJECTS SUFFERING FROM PANIC DISORDER F41 PHOBIC ANXIETY DISORDERS F40 OBSESSIVE-COMPULSIVE DISORDER F42 AND HYPOCHONDRIACAL DISORDER F45 2 2.
SUBJECTS SUFFERING FROM OTHER PSYCHIATRIC ILLNESSES LIKE MOOD DISORDER, PSYCHOSIS, EPILEPSY.
SUBJECTS SUFFERING FROM GENERALIZED ANXIETY DISORDER ASSOCIATED WITH OTHER SERIOUS ILLNESSES THAT WOULD INTERFERE WITH THE TREATMENT.
SUBJECTS SUFFERING FROM HYPERTHYROIDISM, ORGANIC MENTAL DISORDER OR PSYCHOACTIVE SUBSTANCE-RELATED DISORDER F1 SUCH AS EXCESS CONSUMPTION OF AMPHETAMINE-LIKE SUBSTANCES, OR WITHDRAWAL FROM BENZODIAZEPINES.
SUBJECTS WHO ARE ALREADY TAKING ALLOPATHIC MEDICATION FOR GENERALISED ANXIETY DISORDER.
PREGNANT AND LACTATING MOTHERS.

Primary Outcome Measures

Name	Time	Method
REDUCTION IN HAMILTON ANXIETY RATING SCORE	45 DAYS

Secondary Outcome Measures

Name	Time	Method
REDUCTION IN SYMPTOMS OF ANXIETY LIKE PROMINENT TENSION, EXCESSIVE WORRY, FEELING OF APPHREHENSION IN DAY TO DAY EVENTS AND PROBLEMS	REDUCTION IN SYMPTOMS ON 15TH, 30TH AND 45TH DAY

Locations (1): SRI SRI COLLEGE OF AYURVEDIC SCIENCE AND RESEARCH HOSPITAL
🇮🇳
Bangalore, KARNATAKA, India
SRI SRI COLLEGE OF AYURVEDIC SCIENCE AND RESEARCH HOSPITAL
🇮🇳Bangalore, KARNATAKA, India
Dr TARAB
Principal investigator
8078302028
taara.b003@gmail.com